» Articles » PMID: 25725991

IL-25 As a Novel Therapeutic Target in Nasal Polyps of Patients with Chronic Rhinosinusitis

Overview
Date 2015 Mar 2
PMID 25725991
Citations 78
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chronic rhinosinusitis (CRS) with nasal polyps (NPs) in Western populations is associated with TH2 cytokine polarization. IL-25, an IL-17 family cytokine, was recently reported to induce TH2-type immune responses and to contribute to several allergic diseases, such as atopic dermatitis and asthma. However, the role of IL-25 in Asian patients with nasal polyposis remains unclear.

Objective: We sought to determine the role of IL-25 in Asian patients with nasal polyposis and CRS.

Methods: We investigated IL-25 expression and its cellular origins in NPs of human subjects using immunohistochemistry (IHC), quantitative RT-PCR, and ELISA of NP tissues. Correlations between IL-25 expression and expression of other inflammatory markers in NP tissues were also explored. Anti-IL-25 neutralizing antibody was administered in an ovalbumin- and staphylococcal enterotoxin B-induced murine NP model to confirm the function of IL-25 during nasal polypogenesis.

Results: IL-25 expression was upregulated in NP mucosa from patients with CRS with NPs compared with uncinate process tissue from control subjects and those with CRS without NPs. Overexpression of epithelial IL-25 was confirmed by using IHC, and double IHC staining showed that tryptase-positive cells were one of the main sources of IL-25 among immune cells. Furthermore, IL-17 receptor B levels were also increased in immune cells of patients with NPs compared with those in control subjects. In NPs IL-25 mRNA expression positively correlated with the expression of several inflammatory markers, including T-box transcription factor, RAR-related orphan receptor C, GATA3, eosinophil cationic protein, TGF-β1, and TGF-β2. IL-25 was more abundant in the murine NP model compared with control mice, and similar correlations between IL-25 and inflammatory markers were observed in murine models. Anti-IL-25 treatment reduced the number of polyps, mucosal edema thickness, collagen deposition, and infiltration of inflammatory cells, such as eosinophils and neutrophils. This treatment also inhibited expression of local inflammatory cytokines, such as IL-4 and IFN-γ. Furthermore, expression of CCL11, CXCL2, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 in the nasal mucosa was suppressed in the anti-IL-25-treated group.

Conclusion: Our results suggest that IL-25 secreted from the sinonasal epithelia and infiltrating mast cells plays a crucial role in the pathogenesis of CRS with NPs in Asian patients. In addition, our results suggest the novel possibility of treating nasal polyposis with anti-IL-25 therapy.

Citing Articles

Update on the Biological and Clinical Relevance of Mast Cells in Chronic Rhinosinusitis with Nasal Polyps.

Locatello L, Tonon S, Mele V, Santini S, Miani C, Pucillo C Biomedicines. 2024; 12(11).

PMID: 39595211 PMC: 11592168. DOI: 10.3390/biomedicines12112647.


Activation of the PGE-EP2 pathway as a potential drug target for treating eosinophilic rhinosinusitis.

Horikiri K, Taketomi Y, Kondo K, Yamasoba T, Murakami M Front Immunol. 2024; 15:1409458.

PMID: 39015572 PMC: 11250097. DOI: 10.3389/fimmu.2024.1409458.


The Interleukin-15 and Interleukin-8 Axis as a Novel Mechanism for Recurrent Chronic Rhinosinusitis with Nasal Polyps.

Fang K, Chiu Y, Hong R, Cheng P, Cheng P, Liao L Biomedicines. 2024; 12(5).

PMID: 38790942 PMC: 11117578. DOI: 10.3390/biomedicines12050980.


Multi-Disciplinary Expert Perspective on the Management of Type 2 Inflammation-Driven Severe CRSwNP: A Brief Overview of Pathophysiology and Recent Clinical Insights.

Toppila-Salmi S, Bjermer L, Cardell L, Cervin A, Heinikari T, Lehtimaki L J Asthma Allergy. 2024; 17:431-439.

PMID: 38745838 PMC: 11093112. DOI: 10.2147/JAA.S447093.


Retinoic Acid Treatment Mitigates PM2.5-Induced Type 2 Inflammation: Insights into Modulation of Innate Immune Responses.

Lee H, Kim D Int J Mol Sci. 2024; 25(7).

PMID: 38612663 PMC: 11011870. DOI: 10.3390/ijms25073856.